News

AMSilk Secures EUR 52M Strategic Financing to Accelerate Commercial Growth

Funding enables AMSilk to scale industrial production and…

Alchemab Therapeutics initiates Phase 1 clinical trial of ATLX-1282 and announces Series A financing extension

Follows successful completion of pre-clinical activities by Alchemab…

Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder

Suresnes (France), September 8, 2025 – Servier, an independent…

ViCentra Raises $85M to Scale Manufacturing and Accelerate Market Penetration of Kaleido Insulin Patch Pump

Led by new investor Innovation Industries, with matching contributions…

Advanced Medical Solutions Group plc – Notice of Interim Results

Winsford, UK: Advanced Medical Solutions Group plc (AIM:AMS),…

Leucid Bio to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference

London, UK – 28 August 2025 – Leucid Bio ("Leucid" or the…

Kling Bio Announces Collaboration with Sanofi for Accelerated Discovery of Neutralizing Antibodies

Leverages Kling’s technology to discover hard-to-find,…

Neuraxpharm continues international expansion with launch of Neuraxpharm Australia

Avendran Naidu appointed Head of Commercial to lead new affiliate CNS…

Sanofi to acquire next-generation vaccine biotech Vicebio for US$1.6 billion

Sanofi will gain access to Molecular Clamp technology that…

We’d love to hear from you

For more information about Optimum Strategic Communications, please get in touch.

© Optimum Strategic Communications.